{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:37:48Z","timestamp":1773077868435,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s10384-010-0855-4","type":"journal-article","created":{"date-parts":[[2010,11,4]],"date-time":"2010-11-04T12:54:35Z","timestamp":1288875275000},"page":"407-413","source":"Crossref","is-referenced-by-count":12,"title":["Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma"],"prefix":"10.1007","volume":"54","author":[{"given":"Sung Woo","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Mo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,5]]},"reference":[{"key":"855_CR1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A. Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M.s Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268\u20131279.","journal-title":"Arch Ophthalmol"},{"key":"855_CR2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"M.A. Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701\u2013713.","journal-title":"Arch Ophthalmol"},{"key":"855_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archopht.121.6.777","volume":"121","author":"A.M. Fremont","year":"2003","unstructured":"Fremont AM, Lee PP, Mangione CM, et al. Patterns of care for open-angle glaucoma in managed care. Arch Ophthalmol 2003; 121:777\u2013783.","journal-title":"Arch Ophthalmol"},{"key":"855_CR4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archopht.1960.01840010496004","volume":"64","author":"S.M. Drance","year":"1960","unstructured":"Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960;64: 494\u2013501.","journal-title":"Arch Ophthalmol"},{"key":"855_CR5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00417-007-0681-7","volume":"245","author":"I. Tajunisah","year":"2007","unstructured":"Tajunisah I, Reddy SC, Fathilah J. Diurnal variation of intraocular pressure in suspected glaucoma patients and their outcome. Graefes Arch Clin Exp Ophthalmol 2007; 245:1851\u20131857.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"855_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/112067210501500508","volume":"15","author":"F.J. Goni","year":"2005","unstructured":"Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581\u2013590.","journal-title":"Eur J Ophthalmol"},{"key":"855_CR7","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"M.B. Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230\u20131238.","journal-title":"Arch Ophthalmol"},{"key":"855_CR8","first-page":"1641","volume":"111","author":"A. Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al.; Tajimi Study Group, Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004;111: 1641\u20131648.","journal-title":"The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology"},{"key":"855_CR9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The Advanced Glaucoma Intervention Study","year":"2000","unstructured":"The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130:429\u2013440.","journal-title":"Am J Ophthalmol"},{"key":"855_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0161-6420(97)30334-0","volume":"104","author":"N. Koseki","year":"1997","unstructured":"Koseki N, Araie M, Shirato S, Yamamoto S. Effect of trabeculectomy on visual field performance in central 30 degrees field in progressive normal-tension glaucoma. Ophthalmology 1997;104: 197\u2013201.","journal-title":"Ophthalmology"},{"key":"855_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(82)34851-4","volume":"89","author":"S. Abedin","year":"1982","unstructured":"Abedin S, Simmons RJ, Grant WM. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology 1982;89:1\u20136.","journal-title":"Ophthalmology"},{"key":"855_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/IJG.0b013e3181862490","volume":"18","author":"A.J. Sit","year":"2009","unstructured":"Sit AJ. Continuous monitoring of intraocular pressure: rationale and progress toward a clinical device. J Glaucoma 2009;18: 272\u2013279.","journal-title":"J Glaucoma"},{"key":"855_CR13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"E.R. Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337\u2013348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"855_CR14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ijg.0000212264.96864.3e","volume":"15","author":"S. Ishibashi","year":"2006","unstructured":"Ishibashi S, Hirose N, Tawara A, Kubota T. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma. J Glaucoma 2006;15: 354\u2013357.","journal-title":"J Glaucoma"},{"key":"855_CR15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/jop.1990.6.251","volume":"6","author":"D.E. Potter","year":"1990","unstructured":"Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol 1990;6:251\u2013257.","journal-title":"J Ocul Pharmacol"},{"key":"855_CR16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"C.B. Toris","year":"1995","unstructured":"Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514\u20131517.","journal-title":"Arch Ophthalmol"},{"key":"855_CR17","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archopht.1997.01100160538002","volume":"115","author":"L. Wayman","year":"1997","unstructured":"Wayman L, Larsson LI, Maus T, Alm A, Brubaker R. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:1368\u20131371.","journal-title":"Arch Ophthalmol"},{"key":"855_CR18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ICU.0b013e3283249c67","volume":"20","author":"A.M. Bhorade","year":"2009","unstructured":"Bhorade AM. The monocular trial controversy: a critical review. Curr Opin Ophthalmol 2009;20:104\u2013109.","journal-title":"Curr Opin Ophthalmol"},{"key":"855_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0039-6257(80)90099-5","volume":"25","author":"S.M. Drance","year":"1980","unstructured":"Drance SM. The uniocular therapeutic trial in management of elevated IOP. Surv Ophthalmol 1980; 25:203\u2013205.","journal-title":"Surv Ophthalmol"},{"key":"855_CR20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067008","volume":"95","author":"T.J. Zimmerman","year":"1977","unstructured":"Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601\u2013604.","journal-title":"Arch Ophthalmol"},{"key":"855_CR21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9394(00)00527-4","volume":"130","author":"J. Piltz","year":"2000","unstructured":"Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2000;130: 441\u2013453.","journal-title":"Am J Ophthalmol"},{"key":"855_CR22","unstructured":"Kim MS, Kim JM, Park KH, Choi CY. Asymmetry of diurnal intraocular pressure fluctuation between right and left eyes. Acta Ophthalmol [Epub ahead of print Oct 23 2009]."},{"key":"855_CR23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0886-3350(01)00769-6","volume":"27","author":"J.E. McDonald II","year":"2001","unstructured":"McDonald JE II, El-Moatassem Kotb AM, Decker BB. Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions. J Cataract Refract Surg 2001;27:560\u2013564.","journal-title":"J Cataract Refract Surg"},{"key":"855_CR24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2460\/ajvr.1991.52.03.436","volume":"52","author":"D.A. Wilkie","year":"1991","unstructured":"Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in cats. Am J Vet Res 1991;52:436\u2013440.","journal-title":"Am J Vet Res"},{"key":"855_CR25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2460\/ajvr.1991.52.03.432","volume":"52","author":"D.A. Wilkie","year":"1991","unstructured":"Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs. Am J Vet Res 1991;52:432\u2013435.","journal-title":"Am J Vet Res"},{"key":"855_CR26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0161-6420(78)35673-6","volume":"85","author":"W.P. Boger III","year":"1978","unstructured":"Boger WP III, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with openangle glaucoma. Ophthalmology 1978;85:259\u2013267.","journal-title":"Ophthalmology"},{"key":"855_CR27","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.jcrs.2003.12.037","volume":"30","author":"J.E. Thordsen","year":"2004","unstructured":"Thordsen JE, Bower KS, Warren BB, Stutzman R. Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes. J Cataract Refract Surg 2004;30:1702\u20131706.","journal-title":"J Cataract Refract Surg"},{"key":"855_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ajo.2004.02.017","volume":"138","author":"S.M. Brown","year":"2004","unstructured":"Brown SM, Khanani AM, McCartney DL. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Am J Ophthalmol 2004;138:149\u2013151.","journal-title":"Am J Ophthalmol"},{"key":"855_CR29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.117.5.573","volume":"117","author":"M.O. Gordon","year":"1999","unstructured":"Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999; 117:573\u2013583.","journal-title":"Arch Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-010-0855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-010-0855-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-010-0855-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:17:01Z","timestamp":1711930621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-010-0855-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s10384-010-0855-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}